Results 61 to 70 of about 1,113 (191)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema:a review of the current literature [PDF]

, 2017
The first-line therapy for patients with center-involving diabetic macular edema (DME) is with intravitreal anti-vascular endothelial growth factor (VEGF) agents, with or without adjunctive macular laser treatment.
Anand, Astha, Saedon, Habiba, Yit, Yang C.   +2 more
core   +2 more sources

Implantable Drug Delivery Systems for Skeletal Muscles and Eyes

Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.
This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov, Murugan Ramalingam, Hongkai Wu, Toshinori Fujie, Yukinari Nakamura, Takeshi Hori, Yuji Nashimoto, Xuetao Shi, Hirokazu Kaji   +8 more
wiley   +1 more source

Investigation of Diffusion Characteristics through Microfluidic Channels for Passive Drug Delivery Applications

Journal of Drug Delivery, Volume 2016, Issue 1, 2016., 2016
Microfluidics has many drug delivery applications due to the ability to easily create complex device designs with feature sizes reaching down to the 10s of microns. In this work, three different microchannel designs for an implantable device are investigated for treatment of ocular diseases such as glaucoma, age‐related macular degeneration (AMD), and ...
Marcus J. Goudie, Alyssa P. Ghuman, Stephanie B. Collins, Ramana M. Pidaparti, Hitesh Handa, Viness Pillay   +5 more
wiley   +1 more source

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

Ophthalmology and Therapy, 2019
Introduction Diabetic macular oedema (DMO) remains a significant cause of sight loss in the UK. Despite macular laser and anti-VEGF agents, a large proportion of patients remain with persistent DMO.
James F. Young, Andrew Walkden, Amy Stone, Sajjad Mahmood   +3 more
doaj   +1 more source

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Twelve‐Month Follow‐Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes

Journal of Ophthalmology, Volume 2016, Issue 1, 2016., 2016
Purpose. To evaluate the best‐corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods.
Eduardo A. Novais, Mauricio Maia, Paulo Augusto de Arruda Mello Filho, João Rafael de Oliveira Dias, José Maurício B. B. Garcia, Gabriel C. de Andrade, Ricardo N. Louzada, Marcos Ávila, André Maia, J. Fernando Arevalo, Lihteh Wu, Maria Berrocal, Emmerson Badaró, Michel Farah, Enrico Peiretti   +14 more
wiley   +1 more source

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

BMC Ophthalmology, 2018
Background To compare visual function and structural improvements in pseudophakic eyes with diabetic macular oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (IluvienTM) in a ‘real world’ setting.
William Fusi-Rubiano, Chandoshi Mukherjee, Mark Lane, Marie D. Tsaloumas, Nicholas Glover, Andrej Kidess, Alastair K. Denniston, Helen E. Palmer, Avinash Manna, Rupal Morjaria   +9 more
doaj   +1 more source

Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN clinical evidence study in Portugal

Therapeutic Advances in Ophthalmology, 2020
Introduction: The ILUVIEN ® (fluocinolone acetonide) Clinical Evidence in Portugal (ICE-PT) study is a retrospective, multicenter, observational study evaluating the effectiveness and safety of the FAc implant in patients with diabetic macular edema ...
Angela Carneiro, Angelina Meireles, João Paulo Castro Sousa, Carla Teixeira   +3 more
doaj   +1 more source

A review on polymers in ocular drug delivery systems

MedComm – Biomaterials and Applications, Volume 3, Issue 2, June 2024.
Polymers play a pivotal role in ocular drug delivery, revolutionizing treatment approaches. These biomaterials enable controlled and sustained drug release at the targeted site, enhancing bioavailability and patient compliance. From nanosized particle‐based formulations to in situ gelation mechanisms, polymers offer improved treatment options for a ...
Amol C. Bisen, Arpon Biswas, Ayush Dubey, Sachin N. Sanap, Sristi Agrawal, Karan S. Yadav, Vaishali Singh, Priyanka Rawat, Sudhanshu Sagar, Madhav N. Mugale, Rabi S. Bhatta   +10 more
wiley   +1 more source

Comparison of In Vivo Gene Expression Profiling of RPE/Choroid following Intravitreal Injection of Dexamethasone and Triamcinolone Acetonide

Journal of Ophthalmology, Volume 2016, Issue 1, 2016., 2016
Purpose. To identify retinal pigment epithelium (RPE)/choroid genes and their relevant expression pathways affected by intravitreal injections of dexamethasone and triamcinolone acetonide in mice at clinically relevant time points for patient care. Methods. Differential gene expression of over 34,000 well‐characterized mouse genes in the RPE/choroid of
Zeljka Smit-McBride, Elad Moisseiev, Sara P. Modjtahedi, David G. Telander, Leonard M. Hjelmeland, Lawrence S. Morse, Tamer A. Macky   +6 more
wiley   +1 more source